Radiolabeled ligands that bind with similar high affinity to all five SSTs, so-called panSRIF-like ligands, are expected to expand the clinical indications of currently applied predominantly SST2-targeted ligands and to significantly improve tumor targeting, imaging sensitivity, and therapeutic efficacy by crossreactivity to coexpressed SST1, SST3, SST4, and SST5. This evidence concerns the gene SST and neoplasm.